CuraScript Pharmacy Signs Contract With Genentech For Distribution of RAPTIVA(TM)

Date : 10/28/2003 @ 1:13PM
Source : PR Newswire
Stock : Xoma Ltd (MM) (XOMA)
Quote : 2.04  -0.09 (-4.23%) @ 8:00PM
<< BackQuote Chart Financials

 



CuraScript Pharmacy Signs Contract With Genentech For Distribution of RAPTIVA(TM)

CuraScript Pharmacy Signs Contract With Genentech For Distribution of RAPTIVA(TM)

ORLANDO, Fla., Oct. 28 /PRNewswire-FirstCall/ -- CuraScript Pharmacy, Inc., the leading national specialty pharmacy, announced today that it has been selected by Genentech, Inc. to be a participating pharmacy in the Specialty Pharmacy Limited Distribution Network for RAPTIVA(TM) (efalizumab), a new biologic treatment for chronic moderate-to-severe plaque psoriasis in adults age 18 or older.

RAPTIVA, co-developed by Genentech and XOMA Ltd. (NASDAQ:XOMA) in the United States, was approved by the U.S. Food and Drug Administration (FDA) on October 28. RAPTIVA will be available through CuraScript Pharmacy for patients who are prescribed this treatment by their physicians.

Dom Meffe, CuraScript President and CEO, commented, "We are pleased to again be selected by Genentech to launch a new biologic agent. This continues to validate CuraScript's clinical care model that brings value to patients, physicians, healthplans, and pharmaceutical manufacturers. The CuraScript clinical team will deploy a new PsoriasisLogic(TM) patient management program to help maximize clinical outcomes for this exciting new product."

CuraScript is an experienced leader in the specialty pharmacy industry providing specialty medications and support to individuals with chronic illnesses requiring complex, high-cost treatment. CuraScript maximizes healthcare outcomes while helping our healthplan customers manage the growing cost of biotech medications through our industry-leading clinical programs and commitment to patient care. The company has headquarters in Orlando, Florida and five additional satellite facilities located throughout the nation. For additional information on CuraScript and RAPTIVA(TM), call 888-281-5537 or visit http://www.curascript.com/ .

DATASOURCE: CuraScript Pharmacy, Inc.

CONTACT: Valerie Thomas, +1-407-854-8015, or Nicole Visicaro,

+1-407-852-4973, both for CuraScript Pharmacy, Inc.

Web site: http://www.curascript.com/

<< Back


Xoma Ltd (MM) Historical Chart Xoma Ltd (MM) Intraday Chart  
Period


LSE and PLUS quotes are live. NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions :: Contact Us :: Request an Exchange :: Affiliate Scheme
Copyright1999-2008 ADVFN PLC. Copyright and limited reproduction :: Privacy Policy :: Investment Warning :: Advertise with us :: Data accreditations :: Investor Relations :: Press office :: Jobs
ADDITIONAL SERVICES AVAILABLE FROM ADVFN
Upgrade - Click here for more information on ADVFN premium services Money Words - ADVFN Financial Glossary Investor Training ADVFN Financial Bookshop Online Training Academy
42 site:2us 080905 04:04 Stock Message Boards ( 2001 | 2002 | 2003 | 2004 | 2005 | 2005 | 2007 )